Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
Hart- en vaatziekten bij overlevenden van testiscarcinoom: risicofactoren en impact op QoL
aug 2023 | Hartfalen, Myocardinfarct, Uro-oncologie